What happens with your Mounjaro pen after 2 doses?

How much of the pen have you actually used?

A single Mounjaro KwikPen holds four weekly injections, all at the same strength. After dose two you have used exactly half the pen, two injections remain before you need a new supply. This is worth knowing practically: the pen does not need to be refrigerated continuously once you start using it (there is a limited room-temperature window), but the exact storage rules are set out in the Patient Information Leaflet that comes with your medication, and those are the figures to follow rather than any general estimate. The pen arrives through a cold-chain courier in plain, unbranded packaging, and keeping it in the fridge door between injections is the default until the leaflet says otherwise. If you are approaching dose three and wondering what changes, there is a detailed look at what the third dose typically brings in terms of both tolerance and titration timing.

One question our prescribers hear regularly at this stage: "Is there medicine left, or has the pen run out?" The pen has not run out, and if you want to know exactly what to expect when you reach the final injection, our guide to the pen after four doses explains what happens at that point and what to do next. The dose counter on the KwikPen shows remaining injections clearly after each use.

Why does so little seem to have changed after two injections?

This is the most common concern at the two-dose mark, and the short answer is that it is entirely expected. The 2.5 mg strength exists for one reason: to reduce the chance of nausea and other GI effects that come with starting a GLP-1 or dual GIP/GLP-1 medicine. It is not the strength at which most clinical-trial weight outcomes were recorded. The landmark SURMOUNT-1 trial, published in the New England Journal of Medicine, found average body-weight reductions of around 20–21% at the 15 mg maintenance dose over 72 weeks, a dose reached only after a gradual titration that begins exactly where you are now. If you are curious about how things tend to feel right at the start of that journey, our overview of what to expect after the first dose puts the early experience in useful context. Appetite suppression at 2.5 mg can be mild. Some people notice it, some do not. That variability is normal and says nothing about how you will respond once titration progresses.

The NHS patient information for tirzepatide, available on the NHS medicines page, confirms that the starting dose is primarily about tolerability and that the prescriber leads any decision to increase. Expect the clinical picture to develop over the coming weeks, not within days of dose two.

What side effects are most common at this point in treatment?

The first few weeks tend to be when gastrointestinal effects are most noticeable. Nausea, constipation, loose stools, burping, and a general sense of stomach unsettledness are the ones reported most often. Fatigue and mild headaches also appear in early weeks for some people. The pattern is usually that these ease after a few days at each dose level as the body adapts, so if dose two brought more discomfort than dose one, that is not unusual. Small, frequent meals and staying well hydrated genuinely help; leaning on protein and avoiding very fatty foods around injection day is advice many people find useful.

Severe or persistent stomach pain that radiates to the back is different. That symptom needs urgent medical attention because it can be a sign of pancreatitis, a recognised but infrequent risk with GLP-1 medicines that the MHRA highlighted in its January 2026 Drug Safety Update. If you are unsure whether what you are feeling is the usual start-up discomfort or something more serious, contact a clinician rather than waiting. Our support team is available seven days a week for exactly this kind of question.

What comes next, and who decides?

After four weekly injections on 2.5 mg, a prescriber typically reviews your response before considering a move to 5 mg. "Typically" is doing real work in that sentence: titration is not automatic or calendar-guaranteed. If your body is still adjusting, staying at 2.5 mg for longer is entirely reasonable and sometimes the right clinical call. Rushing titration to chase results faster tends to increase side-effect burden. At nume, every repeat order is reviewed by a GPhC-registered Independent Prescriber before it is approved, a real clinician reads your update, not a scoring algorithm. That review is where dose changes are discussed. If you want to understand what the 5 mg dose involves, or are thinking ahead to how the schedule unfolds across the full treatment course, our guide to each dose stage covers the full titration picture. For those considering starting from the beginning, you can check your eligibility with a free consultation reviewed the same day.